PCSK9 and renal pelvis neoplasm: Notably, no causal relationship was observed between PCSK9 inhibitors and the risk of bladder (p = 0.786), thyroid (p = 0.771), pancreatic (p = 0.282), and colorectal cancers (p = 0.795), and kidney (excluding renal pelvis tumors) (p = 0.832), brain (p = 0.108), and esophageal malignancies (p = 0.649) (Figure 3).